Multimodal preclinical imaging is an advanced technology that can track both physiological and structural changes in living organisms, making it a powerful tool for studying disease progression and evaluating drug treatments. This imaging system uses both SPECT and PET + CT imaging techniques, which can be performed in a single instrument and scan, reducing both time and cost. This allows researchers to detect multiple tracers and molecular events at once under the same physiological conditions.
Our advanced imaging system has ultra-high resolution and high sensitivity capabilities of 0.25 mm (SPECT) and < 0.8 mm (PET), providing precise and accurate imaging data. By performing both imaging techniques simultaneously, it reduces the total scanning time by half, improving efficiency and productivity for researchers and pharmaceutical companies.
Using this imaging system, researchers can track changes in real time, providing valuable insights into the effects of drug treatments on disease progression and therapeutic response. This is especially important for longitudinal studies where researchers need to monitor changes over a longer period of time. With its ability to track both physiological and structural changes, multimodal preclinical imaging is a powerful tool for advancing drug discovery projects and improving our understanding of disease processes.
